血容量监测指导超滤生物反馈减少透析中低血压的随机交叉试验
本研究为22周单盲随机交叉试验,纳入常发生症状性透析中低血压的维持性血透患者,比较最佳临床实践联合血容量指导超滤生物反馈与单独最佳临床实践。结果显示生物反馈组症状性IDH发生率为0.10/h,对照组为0.07/h,差异无统计学意义(P=0.29),未减少IDH事件。
要点
- 血容量指导超滤生物反馈未降低症状性透析中低血压发生率。
- 干预组与对照组症状性IDH率分别为0.10/h和0.07/h(P=0.29)。
- 无症状性IDH、透析间期体重增长等次要指标均无差异。
核心结论
- 在易发生透析中低血压的患者中,血容量监测指导的超滤生物反馈未减少症状性IDH事件率。
研究设计与样本
- 22周单盲随机交叉试验,在加拿大卡尔加里五个中心进行,纳入维持性血透且>30% sessions合并症状性IDH的患者。
主要发现
- 生物反馈组症状性IDH发生率为0.10/h(95%CI 0.06-0.14),对照组为0.07/h(95%CI 0.05-0.10),P=0.29。
- 无症状性IDH或单纯症状的发生率或比例无差异,调整随机顺序和研究周后结果一致。
- 最后研究周透析间期体重增长差值(SD)为-0.02(0.8)kg,BNP差值1460(19052)ng/L,心肌肌钙蛋白差值3(86)ng/L,细胞外水/细胞内水比值差值0.05(0.33),超滤率差值1.1(7.0)ml/kg/h,透析恢复时间差值0.43(19.25)小时,均无差异。
临床怎么用
- 对于易发生IDH的维持性血透患者,血容量指导超滤生物反馈未能显示减少症状性IDH,不应常规依赖该技术。
局限性
- 样本量较小(26例完成),可能不足以检测小差异;单盲设计;导入期标准化透析处方和干体重基于临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Intradialytic hypotension (IDH) is associated with morbidity. The effect of blood volume-guided ultrafiltration biofeedback, which automatically adjusts fluid removal rate on the basis of blood volume parameters, on the reduction of IDH was tested in a randomized crossover trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a 22-week, single blind, randomized crossover trial in patients receiving maintenance hemodialysis who had >30% of sessions complicated by symptomatic IDH in five centers in Calgary, Alberta, Canada. Participants underwent a 4-week run-in period to standardize dialysis prescription and dry weight on the basis of clinical examination. Those meeting inclusion criteria were randomized to best clinical practice hemodialysis (control) or best clinical practice plus blood volume-guided ultrafiltration biofeedback (intervention) for 8 weeks, followed by a 2-week washout and subsequent crossover for a second 8-week phase. The primary outcome was rate of symptomatic IDH. RESULTS: Thirty-five participants entered, 32 were randomized, and 26 completed the study. The rate of symptomatic IDH with biofeedback was 0.10/h (95% confidence interval, 0.06 to 0.14) and 0.07/h (95% confidence interval, 0.05 to 0.10) during control (P=0.29). There were no differences in the rate or proportion of sessions with asymptomatic IDH or symptoms alone. Results remained consistent when adjusted for randomization order and study week. There were no differences between intervention and control in the last study week in interdialytic weight gain (difference [SD], -0.02 [0.8] kg), brain natriuretic peptide (1460 [19,052] ng/L), cardiac troponins (3 [86] ng/L), extracellular water-to-intracellular water ratio (0.05 [0.33]), ultrafiltration rate (1.1 [7.0] ml/kg per hour), and dialysis recovery time (0.43 [19.25] hours). CONCLUSION: The use of blood volume monitoring-guided ultrafiltration biofeedback in patients prone to IDH did not reduce the rate of symptomatic IDH events.
引用
- Leung KCW, Quinn RR, Ravani P, et al. Randomized Crossover Trial of Blood Volume Monitoring-Guided Ultrafiltration Biofeedback to Reduce Intradialytic Hypotensive Episodes with Hemodialysis. Clin J Am Soc Nephrol. 2017. PMID: 29018100. doi:10.2215/CJN.01030117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。